|
WO2011066606A1
|
|
Pyranoindole compounds and uses thereof
|
|
CN102596196A
|
|
Methods for inducing programmed cell death
|
|
WO2010042991A1
|
|
Methods of treatment utilising glucan formulations
|
|
EP2334296A1
|
|
Immunomodulating activities
|
|
MX2011001225A
|
|
6-substituted isoflavonoid compounds and uses thereof.
|
|
WO2009103116A1
|
|
Ex vivo cell stimulation
|
|
WO2009103114A1
|
|
Method for producing a bioactive glucan product substantially free of endotoxin contamination
|
|
WO2009103115A1
|
|
Evaluating the therapeutic potential of a glucan
|
|
AU2008243189A1
|
|
Isoflavone metabolites
|
|
US2009233999A1
|
|
Compositions and therapeutic methods involving isoflavones and analogues thereof
|
|
WO2009055848A1
|
|
Methods for sterilizing glucans
|
|
AU2008230055A1
|
|
Methods for Inducing Programmed Cell Death
|
|
CA2641541A1
|
|
Methods for inducing programmed cell death
|
|
AU2008203293A1
|
|
Compositions and therapeutic methods involving isoflavones and analogues thereof
|
|
WO2009003229A1
|
|
2-substituted isoflavonoid compounds, medicaments and uses
|
|
WO2008113100A1
|
|
Method for inducing autophagy
|
|
AU2008200518A1
|
|
Treatment of restenosis
|
|
WO2008052256A1
|
|
Prevention and reversal of chemotherapy-induced peripheral neuropathy
|
|
AU2007203503A1
|
|
Production of isoflavone derivatives
|
|
AU2007201805A1
|
|
Therapeutic methods and compositions involving isoflavones
|
